SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its norovirus oral tablet vaccine at the upcoming 18th International Congress on Infectious Diseases (ICID), taking place from March 1-4, 2018 in Buenos Aires, Argentina.
“The clinical data to be presented at ICID demonstrate that our orally administered norovirus tablet vaccine was well-tolerated and generated robust systemic and local intestinal immune responses,” said Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart. “We believe the quality of the intestinal responses, including both memory and local effector IgA B-cell responses, is unique to our platform and could lead to superior efficacy against an enteric pathogen such as norovirus. Importantly, we did not see any evidence of anti-vector immunity with our oral vaccine, another unique feature of our platform and a potential key advantage over injectable vectored vaccines.”
Presentation Title: Oral immunization of a rAd vector
expressing norovirus VP1 elicits a potent mucosal immune response
without an increase in anti-vector immunity
Date & Time: Saturday, March 3, 2018 from 5:00 – 6:00 PM ART
Authors: Sean Tucker, et al.
All recent presentations are available on the Vaxart website under Newsroom at www.vaxart.com.
Vaxart is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart’s oral vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11. For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, prospects, plans and objectives, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “believe,” “could,” “potential” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop its pipeline of proprietary oral vaccines and direct-acting virals, as well as the anticipated timing of value creating events. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; and the risks described in the “Risk Factors” sections of the Registration Statement on Form S-4 (file no. 333-222009) and of Vaxart’s periodic reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.